CU 20401
Alternative Names: CU-20401Latest Information Update: 10 Feb 2025
At a glance
- Originator Cutia Therapeutics
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Subcutaneous fat disorders
Most Recent Events
- 02 Jan 2024 Phase-II clinical trials in Subcutaneous fat disorders (In volunteers) in China (SC) (NCT06194188)
- 30 Dec 2022 Cutia Therapeutics completes a phase-I/II trial in Subcutaneous fat disorders (In volunteers) in China (SC) (NCT05195541)
- 27 Feb 2022 Phase-I/II clinical trials in Subcutaneous fat disorders (In volunteers) in China (SC) (NCT05195541)